These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 23737243)

  • 1. Pharmacodynamic effects of aripiprazole and ziprasidone with respect to p-glycoprotein substrate properties.
    Holthoewer D; Kirschbaum KM; Frisch J; Hiemke C; Schmitt U
    Pharmacopsychiatry; 2013 Jul; 46(5):175-80. PubMed ID: 23737243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation.
    Cosi C; Waget A; Rollet K; Tesori V; Newman-Tancredi A
    Brain Res; 2005 May; 1043(1-2):32-41. PubMed ID: 15862515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice.
    Kirschbaum KM; Uhr M; Holthoewer D; Namendorf C; Pietrzik C; Hiemke C; Schmitt U
    Neuropharmacology; 2010 Nov; 59(6):474-9. PubMed ID: 20599439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice.
    Leite JV; Guimarães FS; Moreira FA
    Eur J Pharmacol; 2008 Jan; 578(2-3):222-7. PubMed ID: 18021764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
    Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
    Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats.
    Nordquist RE; Risterucci C; Moreau JL; von Kienlin M; Künnecke B; Maco M; Freichel C; Riemer C; Spooren W
    Neuropharmacology; 2008 Feb; 54(2):405-16. PubMed ID: 18054053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective action of an atypical neuroleptic on the mechanisms related to the development of cocaine addiction: a pre-clinical behavioural study.
    Marinho EA; Oliveira-Lima AJ; Wuo-Silva R; Santos R; Baldaia MA; Hollais AW; Longo BM; Berro LF; Frussa-Filho R
    Int J Neuropsychopharmacol; 2014 Apr; 17(4):613-23. PubMed ID: 24345415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of aripiprazole, an atypical antipsychotic, on the motor alterations induced by acute ethanol administration in mice.
    Viana TG; Almeida-Santos AF; Aguiar DC; Moreira FA
    Basic Clin Pharmacol Toxicol; 2013 May; 112(5):319-24. PubMed ID: 23157340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat.
    Bruins Slot LA; Kleven MS; Newman-Tancredi A
    Neuropharmacology; 2005 Dec; 49(7):996-1006. PubMed ID: 16009387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aripiprazole brain concentration is altered in P-glycoprotein deficient mice.
    Wang JS; Zhu HJ; Donovan JL; Yuan HJ; Markowitz JS; Geesey ME; Devane CL
    Schizophr Res; 2009 May; 110(1-3):90-4. PubMed ID: 19239981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour.
    Dahan L; Husum H; Mnie-Filali O; Arnt J; Hertel P; Haddjeri N
    J Psychopharmacol; 2009 Mar; 23(2):177-89. PubMed ID: 18515444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of amisulpride and aripiprazole on progressive-ratio schedule performance: comparison with clozapine and haloperidol.
    den Boon FS; Body S; Hampson CL; Bradshaw CM; Szabadi E; de Bruin N
    J Psychopharmacol; 2012 Sep; 26(9):1231-43. PubMed ID: 21969105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of acute and long-term typical or atypical neuroleptics on morphine-induced behavioural effects in mice.
    Hollais AW; Patti CL; Zanin KA; Fukushiro DF; Berro LF; Carvalho RC; Kameda SR; Frussa-Filho R
    Clin Exp Pharmacol Physiol; 2014 Mar; 41(3):255-63. PubMed ID: 24471703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain.
    Li Z; Ichikawa J; Dai J; Meltzer HY
    Eur J Pharmacol; 2004 Jun; 493(1-3):75-83. PubMed ID: 15189766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective effects of atypical antipsychotic drugs against MPP(+)-induced oxidative stress in PC12 cells.
    Park SW; Lee CH; Lee JG; Kim LW; Shin BS; Lee BJ; Kim YH
    Neurosci Res; 2011 Apr; 69(4):283-90. PubMed ID: 21238512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
    Stahl SM; Shayegan DK
    J Clin Psychiatry; 2003; 64 Suppl 19():6-12. PubMed ID: 14728084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro P-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes.
    Schmitt U; Kirschbaum KM; Poller B; Kusch-Poddar M; Drewe J; Hiemke C; Gutmann H
    Pharmacol Biochem Behav; 2012 Aug; 102(2):312-20. PubMed ID: 22525746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein.
    Inoue T; Osada K; Tagawa M; Ogawa Y; Haga T; Sogame Y; Hashizume T; Watanabe T; Taguchi A; Katsumata T; Yabuki M; Yamaguchi N
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Oct; 39(1):156-62. PubMed ID: 22691713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors.
    Tadori Y; Forbes RA; McQuade RD; Kikuchi T
    Eur J Pharmacol; 2009 Apr; 607(1-3):35-40. PubMed ID: 19217900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.